Weaver C. Barksdale & Associates’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.41M | Sell |
10,979
-28
| -0.3% | -$3.28K | 1.27% | 49 |
|
|
2026
Q1 | $1.32M | Sell |
11,007
-348
| -3% | -$40.2K | 1.26% | 48 |
|
|
2025
Q4 | $1.2M | Sell |
11,355
-1,989
| -15% | -$187K | 1.25% | 44 |
|
|
2025
Q3 | $1.12M | Sell |
13,344
-1,281
| -9% | -$106K | 1.08% | 50 |
|
|
2025
Q2 | $1.16M | Sell |
14,625
-136
| -0.9% | -$10.8K | 1.11% | 51 |
|
|
2025
Q1 | $1.32M | Buy |
14,761
+3,723
| +34% | +$348K | 1.27% | 45 |
|
|
2024
Q4 | $1.1M | Sell |
11,038
-397
| -3% | -$40.9K | 1.05% | 55 |
|
|
2024
Q3 | $1.3M | Sell |
11,435
-608
| -5% | -$72.2K | 1.17% | 50 |
|
|
2024
Q2 | $1.49M | Sell |
12,043
-283
| -2% | -$36.5K | 1.42% | 42 |
|
|
2024
Q1 | $1.63M | Sell |
12,326
-124
| -1% | -$15.3K | 1.49% | 41 |
|
|
2023
Q4 | $1.36M | Sell |
12,450
-4,266
| -26% | -$443K | 1.33% | 45 |
|
|
2023
Q3 | $1.72M | Buy |
16,716
+800
| +5% | +$86.2K | 1.47% | 40 |
|
|
2023
Q2 | $1.84M | Sell |
15,916
-3,811
| -19% | -$433K | 1.82% | 20 |
|
|
2023
Q1 | $2.1M | Sell |
19,727
-1,103
| -5% | -$119K | 1.96% | 15 |
|
|
2022
Q4 | $2.31M | Buy |
20,830
+620
| +3% | +$63.4K | 2.04% | 11 |
|
|
2022
Q3 | $1.74M | Sell |
20,210
-811
| -4% | -$72.4K | 1.75% | 21 |
|
|
2022
Q2 | $1.92M | Buy |
21,021
+4,233
| +25% | +$375K | 1.78% | 22 |
|
|
2022
Q1 | $1.38M | Buy |
16,788
+235
| +1% | +$18.5K | 1.23% | 55 |
|
|
2021
Q4 | $1.27M | Buy |
+16,553
| New | +$1.32M | 1.15% | 56 |
|
|
2017
Q4 | $1.25M | Hold |
23,341
| – | – | 1.32% | 44 |
|
|
2017
Q3 | $1.43M | Hold |
23,341
| – | – | 1.59% | 32 |
|
|
2017
Q2 | $1.43M | Hold |
23,341
| – | – | 1.66% | 22 |
|
|
2017
Q1 | $1.42M | Buy |
23,341
+6,604
| +39% | +$401K | 1.67% | 25 |
|
|
2016
Q4 | $940K | Sell |
16,737
-83
| -0.5% | -$4.86K | 1.52% | 35 |
|
|
2016
Q3 | $1M | Buy |
16,820
+1,294
| +8% | +$75.7K | 1.68% | 8 |
|
|
2016
Q2 | $853K | Hold |
15,526
| – | – | 1.48% | 38 |
|
|
2016
Q1 | $784K | Sell |
15,526
-111
| -0.7% | -$5.44K | 0.59% | 67 |
|
|
2015
Q4 | $788K | Hold |
15,637
| – | – | 0.61% | 59 |
|
|
2015
Q3 | $737K | Hold |
15,637
| – | – | 0.59% | 63 |
|
|
2015
Q2 | $849K | Buy |
15,637
+990
| +7% | +$55.5K | 0.62% | 53 |
|
|
2015
Q1 | $803K | Hold |
14,647
| – | – | 0.6% | 54 |
|
|
2014
Q4 | $794K | Sell |
14,647
-570
| -4% | -$31.8K | 0.64% | 63 |
|
|
2014
Q3 | $861K | Hold |
15,217
| – | – | 0.71% | 35 |
|
|
2014
Q2 | $840K | Hold |
15,217
| – | – | 0.68% | 40 |
|
|
2014
Q1 | $824K | Buy |
+15,217
| New | +$788K | 0.69% | 36 |
|
Other funds holding MRK
Weaver C. Barksdale & Associates's MRK Position: Q2 2026 in Review
Weaver C. Barksdale & Associates reduced its Merck (MRK) stake by 0.25% in Q2 2026, selling an estimated $3.28K and leaving 10,979 shares worth $1.41M. The position accounts for 1.27% of the portfolio, ranked #49.
Weaver C. Barksdale & Associates first reported a position in MRK in Q1 2014 and has held it in 35 quarters since. The position peaked at $2.31M in Q4 2022. 3,824 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Weaver C. Barksdale & Associates held 10,979 shares of Merck worth $1.41M as of Q2 2026.
- Weaver C. Barksdale & Associates sold 28 Merck shares in Q2 2026, an estimated $3.28K.
- Merck made up 1.27% of Weaver C. Barksdale & Associates's portfolio in Q2 2026, its #49 holding.
- Weaver C. Barksdale & Associates first reported a position in Merck in Q1 2014 and has held it in 35 quarters since.
- Weaver C. Barksdale & Associates's Merck position peaked at $2.31M in Q4 2022.
- 3,824 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.